-
-
-
-
-
-
-
Roivant reports positive Phase 2 results for brepocitinib in sarcoidosis
-
-
-
-
-
-
-
Roivant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
-
-
-
-
-
-
-
Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 48c
-
-
-
-
-
-
-
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
-
-
-
-
-
-
-
Roivant Sciences Ltd. (ROIV) Tops Q3 EPS by 634c
-
-
-
-
-
-
-
Roivant Sciences (ROIV) reports higher-than-expected FQ1 loss
-
-
-
-
-
-
-
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2023, and Provides Business Update
-
1,199,620 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

